阿奇霉素联合头孢噻肟治疗AECOPD的效果及对肺功能的影响

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (368 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy of Azithromycin combined with Cefotaxime in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and its influence on pulmonary function. Methods A total of 80 patients with AECOPD admitted to the Department of Emergency Internal Medicine, Bozhou Hospital of Traditional Chinese Medicine, Anhui Province from February 2018 to February 2020 were selected as the study subjects. They were divided into observation group and control group by random number table method, with 40 cases in each group. The control group was treated with Cefotaxime, and the observation group was treated with Azithromycin on the basis of control group. Both groups were treated for one week. The curative effect and the charges of pulmonary function indexes (forced vital capacity [FVC], forced expiratory volume in one second [FEV1], percentage of FEV1 to FVC [FEV1/FVC]), C-reactive protein (CRP) and procalcitonin (PCT) before and after treatment were compared between the two groups. The occurrence of adverse reactions was recorded. Results The total effective rate of the observation group was significantly higher than that of the control group (P ＜ 0.05). After treatment, FVC, FEV1 and FEV1/FVC in two groups were higher than those before treatment, CRP and PCT levels were lower than those before treatment, while the pulmonary function indexes in observation group were all higher than those in control group, CRP and PCT levels were lower than those in control group, the differences were statistically significant (all P ＜ 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Azithromycin combined with Cefotaxime is effective and safe in the treatment of AECOPD.

Key words： Chronic obstructive pulmonary disease Acute exacerbation Azithromycin Cefotaxime Pulmonary function Efficacy Adverse reaction

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Mingming

Cite this article:

LIU Mingming. Effect of Azithromycin combined with Cefotaxime in the treatment of AECOPD and its influence on pulmonary function[J]. 中国医药导报, 2021, 18(15): 145-148.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I15/145

[1] 张弘，蔡柏蔷.慢性阻塞性肺疾病急性加重临床研究进展[J].中国呼吸与危重监护杂志，2016，15（2）：198-202.
[2] 徐海樱，胡永庆.头孢哌酮舒巴坦联合雾化吸入治疗慢性阻塞性肺疾病急性加重期的疗效及对肺功能的影响分析[J].贵州医药，2020，44（5）：706-707.
[3] 毛智荣，屠春林，余艳芳，等.穴位敷贴治疗AECOPD的疗效观察及对肺功能，T淋巴细胞亚群，生活质量的影响[J].广州中医药大学学报，2019，36（8）：1199-1203.
[4] 夏文娟，梅晓冬，王学中.补肺活血胶囊联合阿奇霉素片治疗COPD稳定期患者的临床观察[J].中国药房，2019， 30（10）：112-115.
[5] Gunen H，Kilinc O，Polatli M，et al. Modification of the GOLD recommendations for chronic obstructive pulmonary disease to broaden their usage in Turkey [J]. Expert Rev Respir Med，2016，10（6）：625-628.
[6] Hoepers AT，Menezes MM，Fr?觟de TS. Systematic review of anemia and inflammatory markers in chronic obstructive pulmonary disease [J]. Clin Exp Pharmacol Physiol，2017， 42（3）：231-239.
[7] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2007年修订版）[J].中华内科杂志，2007，4（3）：254-261.
[8] 中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医诊疗指南（2011版）[J].中医杂志，2012，53（1）：80-84.
[9] Miravitlles M，Anzueto A. Role of infection in exacerbations of chronic obstructive pulmonary disease [J]. Curr Opin Pulm Med，2018，21（3）：278-283.
[10] 李军，杨青岩.盐酸氨溴索辅助治疗对AECOPD合并呼吸衰竭患者炎性因子与肺功能的影响[J].中华保健医学杂志，2018，20（5）：422-423.
[11] 徐琛，徐辉甫.中西医结合治疗小儿肺炎的疗效观察及对患儿肺功能的影响[J].湖北中医药大学学报，2018，20（6）：27-30.
[12] Jonsdottir H. Self-management programmers for people living with chronic obstructive pulmonary disease： a call for a reconceptualization [J]. J Clin Nurs，2019，22（5/6）：621-637.
[13] 曾庆为，谢华，宋迪.法舒地尔对AECOPD合并PAH患者肺功能及VEGF的影响[J].西南国防医药，2017，15（27）：1213-1215.
[14] Rasmussen DB，Lange P，Jensen MT. Patients with chronic obstructive pulmonary disease and heart disease can benefit from beta-blocker treatment [J]. Ugeskr Laeger，2019，177（38）：215-218.
[15] 曹利芳，唐超，夏静，等.疏风解毒胶囊治疗AECOPD合并肺部感染的疗效观察[J].中国中医急症，2019，257（9）：138-140.
[16] Shankar PS. Recent advances in the assessment and management of chronic obstructive pulmonary disease [J]. Indian J Chest Dis Allied Sci，2018，50（1）：79-88.
[17] 熊天增.莫西沙星治疗慢性阻塞性肺疾病急性加重期的疗效及对细菌清除率的影响[J].四川医学，2018，39（5）：582-585.
[18] Segal LN，Martinez FJ. Chronic obstructive pulmonary disease subpopulations and phenotyping [J]. J Allergy Clin Immunol，2018，141（6）：1961-1971.
[19] 杨军霞，郭英萌.阿奇霉素对哮喘小鼠气道炎症及细胞因子表达的影响[J].中国医药导报，2019，16（18）：21-24，182.
[20] 王艳，史玉红，李圣，等.阿奇霉素联合辛伐他汀对慢性阻塞性肺疾病合并肺动脉高压患者肺功能的影响[J].现代生物医学进展，2017，17（7）：1328-1330，1338.
[21] 陈晓芸，唐潇潇.阿奇霉素与罗红霉素预防慢性阻塞性肺疾病急性发作的效果比较[J].中国当代医药，2021， 28（1）：46-49.
[22] Rufino R，Lapa E，Silva JR. Cellular and biochemical bases of chronic obstructive pulmonary disease [J]. J Bras Pneumol，2020，32（3）：241-248.
[23] Kotz D，Huibers MJ，Vos R，et al. Principles of confrontational counselling in smokers with chronic obstructive pulmonary disease （COPD）[J]. Med Hypotheses，2018，70（2）：384-386.
[24] 胡克增，陈汉才，陈辉，等.阿奇霉素联合头孢类药物在慢性阻塞性肺疾病急性加重期抗感染治疗中的疗效[J].中华医院感染学杂志，2018，28（3）：360-363.
[25] 薄义，李国照，陈元，等.阿奇霉素联合头孢唑肟抗感染对重症肺部感染患者炎症因子水平的影响[J].中国医药科学，2020，10（8）：19-22.
[26] 卫霞，林英翔，朱建国，等.慢性阻塞性肺疾病急性加重期患者继发真菌感染的危险因素分析[J].中国医药，2016， 11（1）：34-37.
[27] 杨家盛，王燕，林国辉，等.慢性阻塞性肺疾病急性加重期感染的病原菌与PCT、hs-CRP、CD64、WBC感染指标分析[J].中国医药科学，2019，9（24）：17-20.
[28] Tot Veres K. Survival of patients with end-stage chronic obstructive pulmonary disease in relation to smoking habits [J]. Med Pregl，2018，65（3/4）：146-151.